A re-challenging case
Metadata[+] Show full item record
"Immune Checkpoint Inhibitors (ICI) are associated with multiple cardiotoxic effects. Balancing adverse effects with anti-tumor response poses a challenge to treating advanced cancers. The safety of re-starting ICI therapy after an adverse event is unknown. We present the case of a 58-year-old man with stage IV melanoma ICI-related myocarditis and complete heart block (CHB)."--Introduction
Am J Hosp Med 2020 Jan;4(1):2020.006 https://doi.org/10.24150/ajhm/2020.006Am J Hosp Med 2020 Jan;4(1):2020.006 https://doi.org/10.24150/ajhm/2020.006
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.